Clinical Pharmacology and Therapeutics 1996: Vol 60 Index

15 Pages·1996·4 MB·English

Index to volume 60
Author index
A Bochner F (see Capon et al). 1996;60:295-307
Aarbakke J (see Park-Hah et al). 1996;60:68-74 Bodin F (see Corea et al). 1996;60:341-6
Abernethy DR, Woosley RL. 1997 ASCPT Clinical Pharmacology Bonfantino MV (see De Cesaris et al). 1996;60:472-8
Curriculum Review Course. 1996;60:699 Bosincu L (see Faedda et al). 1996;60:561-7
(see Lipsitz et al). 1996;60:461-71 (see Faedda et al). 1996;60:576-81
Breyer S (see Thalhammer et al). 1996;60:645-50
Abiose A (see Grossmann et al). 1996;60:554-60
Abrahamsson B (see Lindahl et al). 1996;60:493-503 Brgsen K (see Poulsen et al). 1996;60:636-44
Alm C (see Carrillo et al). 1996;60:183-90 Brown HV (see Schneider et al). 1996;60:568-75
Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans
Alvan G (see Wakelkamp et al). 1996;60:75-88
Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. have an increased rate of angiotensin converting enzyme
Flavanone absorption after naringin, hesperidin, and citrus admin- inhibitor—associated angioedema. 1996;60:8-13
istration. 1996;60:34-40 Brune K (see Létsch et al). 1996;60:316-25
Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Burggraaf J (see Visser et al). 1996;60:452-60
Wolf KB, Wargin WA, Dren AT. Bidirectional interaction of val- Burgmann H (see Thalhammer et al). 1996;60:645-50
proate and lamotrigine in healthy subjects. 1996;60:145-56
Andriani A (see De Cesaris et al). 1996;60:472-8 €
Apseloff G, Swayne JK, Gerber N. Medical histories may be unre-
Caballero D (see Fernandez de Gatta et al). 1996;60:332-40
liable in screening volunteers for clinical trials. 1996;60:353-6
Cabiac MD (see Humbert et al). 1996;60:265-75
Arendt-Nielsen L (see Poulsen et al). 1996;60:636-44 Calvo V (see Fernandez de Gatta et al). 1996;60:332-40
Arnold JMO (see Bailey et al). 1996;60:25-33 Canal N, Imbimbo BP, Eptastigmine Study Group. Relationship
Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi A, btween pharmacodynamic activity and cognitive effects of
Schapiro MB, Rapoport SI, Soncrant TT. Clinical pharmacoki- eptastigmine in patients with Alzheimer’s disease. 1996;60:218-
netics of arecoline in subjects with Alzheimer’s disease. 28
1996;60:276-82
Cantilena LR Jr, Woosley RL. Survey of clinical pharmacology
Atkinson AJ Jr. A message from the president—come to San Diego, training in the United States and Canada. 1996;60:1-7
California, March 5-8, 1997. 1996;60:699 Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA.
——,, Nordstrom K. The challenge of in-hospital medication use: The influence of CYP2D6 polymorphism and quinidine on the
an opportunity for clinical pharmacology. 1996;60:363-7
disposition and antitussive effect of dextromethorphan in humans.
(Commentary) 1996;60:295-307
Atteneder M (see Thalhammer et al). 1996;60:645-50 Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determi-
Awni WM (see Wong et al). 1996;60:48-53 nants of omeprazole disposition and effect. 1996;60: 157-67
, Wilkinson GR, Wood AJJ. Differences between white sub-
jects and Chinese subjects on the in vivo inhibition of cytochrome
B P450s 2C19, 2D6, and 3A by omeprazole. 1996;60:396-404
Baggott MJ (see Mendelson et al). 1996;60:105-14 Cardoni O (see Corea et al). 1996;60:341-6
Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD. Carignan G (see Laganiére et al). 1996;60:255-64
Erythromycin-felodipine interaction: magnitude, mechanism, and Carrier K (see Laganiére et al). 1996;60:255-64
comparison with grapefruit juice. 1996;60:25-33 Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson
Balboa B (see Serrano et al). 1996;60:589-92 L. Dispositon of fluvoxamine in humans is determined by the
Balian JD (see Marinac et al). 1996;60:138-44 polymorphic CYP2D6 and also by the CYPIA2 activity.
Bank AJ (see Rector et al). 1996;60:667-74 1996;60: 183-90
Barbhaiya RH (see Knupp et al). 1996;60:535-42 Cavallo A (see De Cesaris et al). 1996;60:472-8
(see Vachharajani et al). 1996;60:283-94 Cavanaugh J (see Wong et al). 1996;60:48-53
Barr DM (see Paine et al). 1996;60: 14-24 Chang WH (see Lane et al). 1996;60:696-8 (Letter)
Bartoli E (see Faedda et al). 1996;60:561-7 Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxida-
(see Faedda et al). 1996;60:576-81 tive metabolites of acetaminophen after consumption of water-
Bateman DN (see Hartigan-Go et al). 1996;60:89-98 cress by human volunteers. 1996;60:65 1-60
(see Hartigan-Go et al). 1996;60:543-53 Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC,
Bélanger PM (see Hamelin et al). 1996;60:512-21 Neill JR, Martin WL, Hays LR, Wedlund PJ. The cytochrome
Bend JR (see Bailey et al). 1996;60:25-33 P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and
Benowitz N (see Gries et al). 1996;60:385-95 influence on clinical outcomes in psychiatry. 1996;60:522-34
Berardi A (see Asthana et al). 1996;60:276-82 Chiba K (see Kubota et al). 1996;60:661-6
Bertilsson L (see Carrillo et al). 1996;60:183-90 Chin C (see Lerman et al). 1996;60:485-92
Bertocchi F (see De Cesaris et al). 1996;60:472-8 Choi KH (see Park-Hah et al). 1996;60:68-74
Bigelow GE (see Strain et al). 1996;60:206-17 Chou WH (see Chen et al). 1996;60:522-34
Birnboeck H (see Weber et al). 1996;60:124-37 Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL.
Bjornsson TD (see Hellriegel et al). 1996;60:601-7 (Commentary) Multiple-dose pharmacokinetics, pharmacodynamics, and safety
Blaschke TF (see Grossmann et al). 1996;60:554-60 of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy
Blouin RA (see Chen et al). 1996;60:522-34 subjects. 1996;60:687-95
Blumer JL (see Sullivan et al). 1996;60:405-13 Coakley DF (see Knupp et al). 1996;60:535-42
(see Sullivan et al). 1996;60:414-23 Cohen AF (see van Griensven et al). 1996;60:504-11
(see Sullivan et al). 1996;60:424-34 —— (see Visser et al). 1996;60:452-60
CLINICAL PHARMACOLOGY & THERAPEUTICS DECEMBER 1996 705
CLINICAL PHARMACOLOGY & THERAPEUTICS
706 Author index DECEMBER 1996
Connelly CM (see Lipsitz et al). 1996;60:461-71 Georgopoulos A (see Thalhammer et al). 1996;60:645-50
Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Gerber N (see Apseloff et al). 1996;60:353-6
Provvidenza M, Meilenbrock S, Sullivan J, Bodin F. Valsartan, a Ghali JK (see Liendo et al). 1996;60:593-8
new angiotensin II antagonist for the treatment of essential hyper- Gibson DM (see Cilla et al). 1996;60:687-95
tension: a comparative study of the efficacy and safety against Gidal BE (see Anderson et al). 1996;60:145-56
amlodipine. 1996;60:34 1-6 Gillies BS (see Paine et al). 1996;60:14-24
Goernert L (see Laganiére et al). 1996;60:255-64
D Gorski JC (see Jones et al). 1996;60:374-84
Gosse ME, DiMasi JA, Nelson TF. Recombinant protein and
Dahl ML (see Carrillo et al). 1996;60:183-90 therapeutic monoclonal antibody drug development in the United
Daims RM (see Schneider et al). 1996;60:568-75 States from 1980 to 1994. 1996;60:608-18 (Commentary)
Daly AK (see Hartigan-Go et al). 1996;60:89-98 Gow R (see Lerman et al). 1996;60:485-92
Danz C (see Capon et al). 1996;60:295-307 Graninger W (see Thalhammer et al). 1996;60:645-50
Daus JC (see Marinac et al). 1996;60:138-44 Granneman GR (see Wong et al). 1996;60:48-53
Davies RF (see Laganiére et al). 1996;60:255-64 Graselli U (see Schmetterer et al). 1996;60:199-205
De Cesaris R, Ranieri G, Andriani A, Lamontanara G, Cavallo A, Graves SW (see Liendo et al). 1996;60:593-8
Bonfantino MV, Bertocchi F. Effects of benazepril and nicardi- Gray JD. A message from the Education Committee chairman.
pine on microalbuminuria in normotensive and hypertensive 1996;60:236
patients with diabetes. 1996;60:472-8 Greig NH (see Asthana et al). 1996;60:276-82
Dempsey E (see Lerman et al). 1996;60:485-92 Gries JM, Benowitz N, Verotta D. Chronopharmacokinetics of
Deng HC (see Lane et al). 1996;60:696-8 (Letter) nicotine. 1996;60:385-95
DiMasi JA (see Gosse et al). 1996;60:608-18 (Commentary) Griffin MR (see Brown et al). 1996;60:8-13
Dominguez-Gil A (see Fernandez de Gatta et al). 1996;60:332-40 Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB.
Dooijewaard G (see van Griensven et al). 1996;60:504-11 Morphine-induced venodilation in humans. 1996;60:554-60
Dren AT (see Anderson et al). 1996;60:145-56 Gyr K (see Kaufmann et al). 1996;60:62-7
Dubray C (see Humbert et al). 1996;60:265-75
Dukes GE (see Knupp et al). 1996;60:535-42
Dunton AW. A message from the Ethics Committee chairman.
H
1996;60:360
Haefeli WE (see Kaufmann et al). 1996;60:62-7
(see Strobel et al). 1996;60:435-43
E
Haehner BD (see Jones et al). 1996;60:374-84
Eichler HG (see Schmetterer et al). 1996;60:199-205 Hak LJ (see Knupp et al). 1996;60:535-42
Elliott WJ. Higher incidence of discontinuation of angiotensin con- Hall SD (see Jones et al). 1996;60:374-84
verting enzyme inhibitors due to cough in black subjects. Hamelin BA, Turgeon J, Vallée F, Bélanger PM, Paquet F, LeBel M.
1996;60:582-8 The disposition of fluoxetine but not sertraline is altered in poor
Elmenyawi I (see Thalhammer et al). 1996;60:645-50 metabolizers of debrisoquin. 1996;60:512-21
Eptastigmine Study Group (see Canal et al). 1996;60:218-28 Hardwick JP (see Zhou et al). 1996;60:191-8
Hardy E. Factors often not considered before a multicenter trial is
started. 1996;60:121-3 (Commentary)
F
Harris SJ (see Anderson et al). 1996;60:145-56
Faedda R, Pirisi M, Satta A, Bosincu L, Bartoli E. Hartigan-Go K, Bateman DN, Daly AK, Thomas SHL.
Immunosuppressive treatment of Berger’s disease. 1996;60:561-7 Stereoselective cardiotoxic effects of terodiline. 1996;60:89-
' ‘ i; . Regression of Henoch-Schénlein 98
disease with intensive immunosuppressive treatment. 1996; ——, ——, Nyberg G, Méartensson E, Thomas SHL.
60:576-81 Concentration-related pharmacodynamic effects of thioridazine
Falk RJ (see Knupp et al). 1996;60:535-42 and its metabolites in humans. 1996;60:543-53
Feldman RD, Logan AG, Schmidt ND. Dietary salt restriction Hauck WW (see Hellriegel et al). 1996;60:601-7 (Commentary)
increases vascular insulin resistance. 1996;60:444-51 Hays LR (see Chen et al). 1996;60:522-34
Fernandez I (see Mendelson et al). 1996;60:105-14 Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in
Fernandez de Gatta MdM, Calvo V, Hernandez JM, Caballero D, bioavailability is related to the extent of absorption: implications
San Miguel JF, Dominguez-Gil A. Cost-effectiveness analysis of for bioavailability and bioequivalence studies. 1996;60:601-7
serum vancomycin concentration monitoring in patients with (Commentary)
hematologic malignancies. 1996;60:332-40 Hernandez JM (see Fernandez de Gatta et al). 1996;60:332-40
Ferrari MD (see Visser et al). 1996;60:452-60 Hoffman BB (see Grossmann et al). 1996;60:554-60
Findl O (see Schmetterer et al). 1996;60:199-205 Hollenstein U (see Thalhammer et al). 1996;60:645-50
Flockhart DA (see Marinac et al). 1996;60:138-44 Holloway HW (see Asthana et al). 1996;60:276-82
Fogari R (see Corea et al). 1996;60:341-6 Holtzman JL (see Zhou et al). 1996;60:191-8
Foris K (see Laganiére et al). 1996;60:255-64 Hopfgartner G (see Weber et al). 1996;60: 124-37
Fowler PA (see Visser et al). 1996;60:452-60 Hérl WH (see Thalhammer et al). 1996;60:645-50
Foxworth JW (see Marinac et al). 1996;60:138-44 Howard DR (see Lerman et al). 1996;60:485-92
Fraser HS. Reserpine: a tragic victim of myths, marketing, and Hu OYP (see Lane et al). 1996;60:696-8 (Letter)
fashionable prescribing. 1996;60:368-73 (Commentary) Hu WH (see Lane et al). 1996;60:696-8 (Letter)
Huang Jd (see Tseng et al). 1996;60:177-82
Huang SM (see Lane et al). 1996;60:696-8 (Letter)
G
Huisman LGM (see van Griensven et al). 1996;60:504-11
Gabrielsson J (see Wakelkamp et al). 1996;60:75-88 Humbert H, Cabiac MD, Dubray C, Lavéne D. Human pharmaco-
Gambertoglio JG (see Peter and Gambertoglio). 1996;60: 168-76 kinetics of dihydroergotamine administered by nasal spray.
Garnett WR (see Vachharajani et al). 1996;60:283-94 1996;60:265-75
Geisslinger G (see Létsch et al). 1996;60:316-25 Humphries LL (see Chen et al). 1996;60:522-34
CLINICAL PHARMACOLOGY & THERAPEUTICS
VOLUME 60, NUMBER 6 Author index 707
Lawson-Matthew P (see Morice et al). 1996;60:675-8
LeBel M (see Hamelin et al). 1996;60:512-21
Iga T (see Kotaki et al). 1996;60:229-35
Lennernis H (see Lindahl et al). 1996;60:493-503
Imbimbo BP (see Canal et al). 1996;60:218-28
Lerman J, Sims C, Sikich N, Gow R, Chin C, Dempsey E, Howard
Innocenti P (see Corea et al). 1996;60:341-6
DR, Keung ACF. Pharmacokinetics of the active metabolite
Ishizaki T (see Kubota et al). 1996;60:661-6
(MDL 74,156) of dolasetron mesylate after oral or intravenous
Ito K (see Kotaki et al). 1996;60:229-35
Iversen E (see Ngrregaard et al). 1996;60:679-86 administration to anesthetized children. 1996;60:485-92
Levy RH (see Anderson et al). 1996;60:145-56
Liebson IA (see Strain et al). 1996;60:206-17
J Liendo C, Ghali JK, Graves SW. A new interference in some
Jakobsen HB (see Ngrregaard et al). 1996;60:679-86 digoxin assays: anti-murine heterophilic antibodies. 1996;60:593-
Jalava KM (see Neuvonen and Jalava). 1996;60:54-61 8
Jiménez CM (see Serrano et al). 1996;60:589-92 Lin KA (see Rector et al). 1996;60:667-74
Johnson JV (see Ameer et al). 1996;60:34-40 Lindahl A, Sandstr6m R, Ungell AL, Abrahamsson B, Knutson TW,
Jones CR (see Weber et al). 1996;60:124-37 Knutson L, Lennernis H. Jejunal permeability and hepatic extrac-
Jones DR, Gorski JC, Haehner BD, O’Mara EM Jr, Hall SD. tion of fluvastatin in humans. 1996;60:493-503
Determination of cytochrome P450 3A4/5 activity in vivo with Linder L (see Strobel et al). 1996;60:435-43
dextromethorphan N-demethylation. 1996;60:374-84 Linnet K, Wiborg O. Steady-state serum concentrations of the neu-
Jones RT (see Mendelson et al). 1996;60:105-14 roleptic perphenazine in relation to CYP2D6 genetic polymor-
Jonkman JHG (see Weber et al). 1996;60: 124-37 phism. 1996;60:41-7
Jgrgensen S (see Ngrregaard et al). 1996;60:679-86 Lipsitz LA, Connelly CM, Kelley-Gagnon M, Kiely DK, Abernethy
D, Waksmonski C. Cardiovascular adaptation to orthostatic stress
during vasodilator therapy. 1996;60:461-71
K
Logan AG (see Feldman et al). 1996;60:444-51
Kaga K( see Kotaki et al). 1996;60:229-35 Létsch J, Stockmann A, Kobal G, Brune K, Waibel R, Schmidt N,
Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer Geisslinger G. Pharmacokinetics of morphine and its glu-
UA, Haefeli WE. N-Acetyltransferase 2 polymorphism in patients curonides after intravenous infusion of morphine and morphine-
infected with human immunodeficiency virus. 1996;60:62-7 6-glucuronide in healthy volunteers. 1996;60:316-25
Kaul S (see Knupp et al). 1996;60:535-42 Lunell E (see Vanakoski et al). 1996;60:308-15
Kelley-Gagnon M (see Lipsitz et al). 1996;60:461-71 Liischer TF (see Strobel et al). 1996;60:435-43
Kennedy BP (see Mills et al). 1996;60:99-104 Lysaa R (see Park-Hah et al). 1996;60:68-74
Kerry N (see Capon et al). 1996;60:295-307
Keung ACF (see Lerman et al). 1996;60:485-92 M
Kiely DK (see Lipsitz et al). 1996;60:461-71
Klemetsdal B (see Park-Hah et al). 1996;60:68-74 Mandema JW, Stanski DR. Population pharmacodynamic model
Kluft K (see van Griensven et al). 1996;60:504-11 for ketorolac analgesia. 1996;60:619-35
Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH, Mao Z (see Chen et al). 1996;60:522-34
van der Horst CM, Kaul S, Barbhaiya RH, Dukes GE. Disposition Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen
of didanosine in HIV-seropositive patients with normal renal R, Flockhart DA. Determination of CYP2C19 phenotype in black
function or chronic renal failure: influence of hemodialysis and Americans with omeprazole: correlation with genotype.
continuous ambulatory peritoneal dialysis. 1996;60:535-42 1996;60: 138-44
Knutson L (see Lindahl et al). 1996;60:493-503 Marsh CL (see Paine et al). 1996;60:14-24
Knutson TW (see Lindahl et al). 1996;60:493-503 Martensson E (see Hartigan-Go et al). 1996;60:543-53
Kobal G (see Létsch et al). 1996;60:316-25 Martin WL (see Chen et al). 1996;60:522-34
Kotaki H, Tayama N, Ito K, Mitomi N, Tezuka K, Kaga K, Sawada Mayer G (see Thalhammer et al). 1996;60:645-50
Y, Iga T. Safe and effective topical application dose of lidocaine McGilveray I (see Laganiére et al). 1996;60:255-64
for surgery with laryngomicroscopy. 1996;60:229-35 McVicar JP (see Paine et al). 1996;60:14-24
Krejcy K (see Schmetterer et al). 1996;60:199-205 Meek QC (see Chen et al). 1996;60:522-34
Kroon R (see van Griensven et al). 1996;60:504-11 Meilenbrock S (see Corea et al). 1996;60:341-6
Kubo SH (see Rector et al). 1996;60:667-74 Melby AK (see Mendelson et al). 1996;60:105-14
Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’- Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK,
hydroxylation in an extended Japanese population. 1996;60:661- Baggott MJ. Buprenorphine and naloxone interactions in opiate-
6 dependent volunteers. 1996;60: 105-14
Kunze KL (see Paine et al). 1996;60:14-24 Meyer FP, Tréger U, R6h] FW. Adverse nondrug reactions: an
update. 1996;60:347-52
Meyer UA (see Kaufmann et al). 1996;60:62-7
L
Mikkelsen KL (see Norregaard et al). 1996;60:679-86
Laganiére S, Davies RF, Carignan G, Foris K, Goernert L, Carrier Mikus G (see Capon et al). 1996;60:295-307
K, Pereira C, McGilveray I. Pharmacokinetic and pharmacody- Mills PJ, Ziegler MG, Nelesen RA, Kennedy BP. The effects of the
namic interactions between diltiazem and quinidine. 1996; menstrual cycle, race, and gender on adrenergic receptors and
60:255-64 agonists. 1996;60:99-104
Lagerstrom PO (see Caraco et al). 1996;60:157-67 Mitomi N (see Kotaki et al). 1996;60:229-35
Lai AA (see Anderson et al). 1996;60:145-56 Mohr SN (see Chen et al). 1996;60:65 1-60
Lai MD (see Tseng et al). 1996;60:177-82 Morgenthien EA (see Vachharajani et al). 1996;60:283-94
Lai ML (see Tseng et al). 1996;60:177-82 Morice AH, Morris D, Lawson-Matthew P. A comparison of nebu-
Lamontanara G (see De Cesaris et al). 1996;60:472-8 lized budesonide with oral prednisolone in the treatment of exac-
Lane HY, Deng HC, Huang SM, Hu WH, Chang WH, Hu OYP. erbations of obstructive pulmonary disease. 1996;60:675-8
Low frequency of dextromethorphan O-demethylation deficiency Morris D (see Morice et al). 1996;60:675-8
in a Chinese population. 1996;60:696-8 (Letter) Mullen KA (see Rector et al). 1996;60:667-74
Lavéne D (see Humbert et al). 1996;60:265-75 Muller LM (see Visser et al). 1996;60:452-60
CLINICAL PHARMACOLOGY & THERAPEUTICS
708 Author index DECEMBER 1996
Myers CM (see Sullivan et al). 1996;60:405-13 Reele SB. Publishing Summary Basis of Approval. 1996;60:357
—— (see Sullivan et al). 1996;60:414-23 (Letier)
(see Sullivan et al). 1996;60:424-34 Rodriguez I (see Carrillo et al). 1996;60:183-90
Rohl FW (see Meyer et al). 1996;60:347-52
Rosenkranz AR (see Thalhammer et al). 1996;60:645-50
N
Rouseff RL (see Ameer et al). 1996;60:34-40
Neill JR (see Chen et al). 1996;60:522-34
Nelesen RA (see Mills et al). 1996;60:99-104 Ss
Nelson SD (see Slattery et al). 1996;60:241-6 (Commentary)
Nelson TF (see Gosse et al). 1996;60:608-18 (Commentary) Sandstrém R (see Lindahl et al). 1996;60:493-503
Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma San Miguel JF (see Fernandez de Gatta et al). 1996;60:332-40
concentrations of lovastatin and lovastatin acid. 1996;60:54-61 Satta A (see Faedda et al). 1996;60:561-7
, Varhe A, Olkkola KT. The effect of ingestion time interval on —— (see Faedda et al). 1996;60:576-81
the interaction between itraconazole and triazolam. 1996;60:326- Sawada Y (see Kotaki et al). 1996;60:229-35
31 Schapiro MB (see Asthana et al). 1996;60:276-82
Nordstrom K (see Atkinson and Nordstrom). 1996;60:363-7 Schmaldienst S (see Thalhammer et al). 1996;60:645-50
(Commentary) Schmetterer L, Wolzt M, Krejcy K, Graselli U, Findl O, Eichler
Ngrregaard J, Jorgensen S, Mikkelsen KL, Tgnnesen P, Iversen E, HG, Singer EA. Cerebral and ocular hemodynamic effects of
Sgrensen T, Sgeberg B, Jakobsen HB. The effect of ephedrine sumatriptan in the nitroglycerin headache model. 1996;60:199-
plus caffeine on smoking cessation and postcessation weight gain. 205
1996;60:679-86 Schmidt N (see Létsch et al). 1996;60:316-25
Nyberg G (see Hartigan-Go et al). 1996;60:543-53 Schmidt ND (see Feldman et al). 1996;60:444-51
Schmitt R (see Weber et al). 1996;60:124-37
Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM,
oO Brown HV. Efficacy of buspirone in smoking cessation: a
Olkkola KT (see Neuvonen et al). 1996;60:326-31 placebo-controlled trial. 1996;60:568-75
Olmstead RE (see Schneider et al). 1996;60:568-75 Schoemaker RC (see van Griensven et al). 1996;60:504-11
O’Mara EM Jr (see Jones et al). 1996;60:374-84 (see Visser et al). 1996;60:452-60
Owen R (see Marinac et al). 1996;60:138-44 Schwartz JB. A message from the Scientific Program Committee
chairperson: 1997 annual meeting—March 5-7 (ASCPT), March
8 (ASCPT/ASPET). 1996;60:115
P Sedman AJ (see Cilla et al). 1996;60:687-95
Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar Seppila T (see Vanakoski et al). 1996;60:308-15
JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of Serrano JS, Jiménez CM, Serrano MI, Balboa B. A possible inter-
midazolam by the human intestine. 1996;60:14-24 action of potential clinical interest between digoxin and acarbose.
Paintaud G (see Wakelkamp et al). 1996;60:75-88 1996;60:589-92
Paquet F (see Hamelin et al). 1996;60:512-21 Serrano MI (see Serrano et al). 1996;60:589-92
Park SS (see Zhou et al). 1996;60:191-8 Shen DD (see Paine et al). 1996;60:14-24
Park-Hah JO, Klemetsdal B, Lysaa R, Choi KH, Aarbakke J. Shi H (see Wong et al). 1996;60:48-53
Thiopurine methyltransferase activity in a Korean population Shyu WC (see Vachharajani et al). 1996;60:283-94
sample of children. 1996;60:68-74 Sievi E (see Vanakoski et al). 1996;60:308-15
Peeters PAM (see Weber et al). 1996;60:124-37 Sikich N (see Lerman et al). 1996;60:485-92
Pereira C (see Laganieére et al). 1996;60:255-64 Simper D (see Strobel et al). 1996;60:435-43
Perkins JD (see Paine et al). 1996;60: 14-24 Sims C (see Lerman et al). 1996;60:485-92
Peter K, Gambertoglio JG. Zidovudine phosphorylation after short- Sindrup SH (see Poulsen et al). 1996;60:636-44
term and long-term therapy with zidovudine in patients infected Singer EA (see Schmetterer et al). 1996;60:199-205
with the human immunodeficiency virus. 1996;60: 168-76 Slattery JT, Nelson SD, Thummel KE. The complex inter-
Peterli B (see Kaufmann et al). 1996;60:62-7 action between ethanol and acetaminophen. !996;60:241-6
Pihlstrom B (see Zhou et al). 1996;60:191-8 (Commentary)
Pirisi M (see Faedda et al). 1996;60:561-7 Sloan K (see Schneider et al). 1996;60:568-75
(see Faedda et al). 1996;60:576-81 Snowden M (see Brown et al). 1996;60:8-13
Porcellati C (see Corea et al). 1996;60:341-6 Sgeberg B (see Ngrregaard et al). 1996;60:679-86
Posvar EL (see Cilla et al). 1996;60:687-95 Somogyi AA (see Capon et al). 1996;60:295-307
Poulsen L, Arendt-Nielsen L, Brésen K, Sindrup SH. The hypoal- Soncrant TT (see Asthana et al). 1996;60:276-82
gesic effect of tramadol in relation to CYP2D6. 1996;60:636-44 Sgrensen T (see Ngrregaard et al). 1996;60:679-86
Preston KL (see Strain et al). 1996;60:206-17 Spence JD (see Bailey et al). 1996;60:25-33
Provvidenza M (see Corea et al). 1996;60:341-6 Stanski DR (see Mandema and Stanski). 1996;60:619-35
Putz D (see Thalhammer et al). 1996;60:645-50 Steinberg C (see Schneider et al). 1996;60:568-75
Stockmann A (see Létsch et al). 1996;60:316-25
Strain EC, Preston KL, Liebson IA, Bigelow GE. Opioid antagonist
R effects of dezocine in opioid-dependent humans. 1996;60:
Raasch RH (see Knupp et al). 1996;60:535-42 206-17
Raffaele KC (see Asthana et al). 1996;60:276-82 Strobel WM, Liischer TF, Simper D, Linder L, Haefeli WE.
Ranieri G (see De Cesaris et al). 1996;60:472-8 Substance P in human hand veins in vivo: tolerance, efficacy,
Rapoport SI (see Asthana et al). 1996;60:276-82 potency, and mechanism of venodilator action. 1996;60:
Ray WA (see Brown et al). 1996;60:8-13 435-43
Rector TS, Bank AJ, Tschumperlin LK, Mullen KA, Lin KA, Kubo Stuurman T (see van Griensven et al). 1996;60:504-11
SH. Abnormal desmopressin-induced forearm vasodilatation in Sullivan J (see Corea et al). 1996;60:341-6
patients with heart failure: dependence on nitric oxide synthase Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL.
activity. 1996;60:667-74 Analysis of the variability in the pharmacokinetics and pharma-
CLINICAL PHARMACOLOGY & THERAPEUTICS
VOLUME 60, NUMBER 6 Author index 709
codynamics of bumetanide in critically ill infants. 1996;60:414- Ww
23 Wagner BE (see Knupp et al). 1996;60:535-42
—_, -—_—_, —, . . Dose-ranging evaluation of Waibel R (see Létsch et al). 1996;60:316-25
bumetanide pharmacodynamics in critically ill infants. Wakelkamp M, Alvan G, Gabrielsson J, Paintaud G.
1996;60:424-34 Pharmacodynamic modeling of furosemide tolerance after multi-
; , : ; . Pharmacokinetics of bumetanide in ple intravenous administration. 1996;60:75-88
critically ill infants. 1996;60:405-13 Waksmonski C (see Lipsitz et al). 1996;60:461-71
Svensson JO (see Carrillo et al). 1996;60:183-90 Wang SL (see Tseng et al). 1996;60:177-82
Swayne JK (see Apseloff et al). 1996;60:353-6 Wargin WA (see Anderson et al). 1996;60:145-56
Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP,
Peeters PAM, Jonkman JHG, Jones CR. Pharmacokinetics and
¥ pharmacodynamics of the endothelin-receptor antagonist bosen-
Taeschner W (see Kaufmann et al). 1996;60:62-7 tan in healthy human subjects. 1996;60:124-37
Tangphao O (see Grossmann et al). 1996;60:554-60 Wedlund PJ (see Chen et al). 1996;60:522-34
Tayama N (see Kotaki et al). 1996;60:229-35 Wehbe TW, Warth JA. A case of bleeding requiring hospitalization
that was likely caused by an interaction between warfarin and lev-
Tezuka K (see Kotaki et al). 1996;60:229-35
Thalhammer F, Schmaldienst S, Elmenyawi I, Atteneder M, amisole (1996;59:360-2). 1996;60:137 (Correction)
Weiner GJ (see Weiner and Weiner). 1996;60:247-54
Burgmann H, Hollenstein U, Georgopoulos A, Graninger W, Putz
(Commentary)
D, Rosenkranz AR, Mayer G, Hérl WH, Breyer S. Multiple-dose Weiner M, Weiner GJ. The kinetics and dynamics of responses to
pharmacokinetics of cefpirome in long-term hemodialysis with
placebo. 1996;60:247-54 (Commentary)
high-flux membranes. 1996;60:645-50 Weinshilboum RM. A message from the Finance Committee chair-
Thomas SHL (see Hartigan-Go et al). 1996;60:89-98 person. 1996;60:480
(see Hartigan-Go et al). 1996;60:543-53 Weintraub RA (see Ameer et al). 1996;60:34-40
Thummel KE (see Paine et al). 1996;60:14-24 Welm S (see Mendelson et al). 1996;60: 105-14
(see Slattery et al). 1996;60:241-6 (Commentary) Wenk M (see Kaufmann et al). 1996;60:62-7
Tonnesen P (see Ngrregaard et al). 1996;60:679-86 Whitfield LR (see Cilla et al). 1996;60:687-95
Tran LT (see Bailey et al). 1996;60:25-33 Wiborg O (see Linnet and Wiborg). 1996;60:41-7
Tréger U (see Meyer et al). 1996;60:347-52 Wilkinson GR (see Caraco et al). 1996;60:396-404
Tschumperlin LK (see Rector et al). 1996;60:667-74 Willsie SK (see Marinac et al). 1996;60:138-44
Tseng CY, Wang SL, Lai MD, Lai ML, Huang Jd. Formation of Witte MK (see Sullivan et al). 1996;60:405-13
morphine from codeine in Chinese subjects of different CYP2D6 (see Sullivan et al). 1996;60:414-23
genotypes. 1996;60:177-82 —— (see Sullivan et al). 1996;60:424-34
Wolf KB (see Anderson et al). 1996;60:145-56
Turgeon J (see Hamelin et al). 1996;60:512-21 Wolzt M (see Schmetterer et al). 1996;60:199-205
Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR. Effects
U of divalproex sodium on amitriptyline and nortriptyline pharma-
cokinetics. 1996;60:48-53
Ungell AL (see Lindahl et al). 1996;60:493-503
Wood AJJ (see Caraco et al). 1996;60:157-67
(see Caraco et al). 1996;60:396-404
v Woosley RL (see Abernethy and Woosley). 1996;60:699
Vachharajani NN, Shyu WC, Garnett WR, Morgenthien EA, (see Cantilena and Woosley). 1996;60:1-7
Barbhaiya RH. The absolute bioavailability and pharmacokinetics Wrighton SA (see Zhou et al). 1996;60:191-8
of butorphanol nasal spray in patients with hepatic impairment.
1996;60:283-94 Y
Vallée F (see Hamelin et al). 1996;60:512-21 Yamashita TS (see Sullivan et al). 1996;60:405-13
Vanakoski J, Seppala T, Sievi E, Lunell E. Exposure to high ambi- (see Sullivan et al). 1996;60:414-23
ent temperature increases absorption and plasma concentrations —— (see Sullivan et al). 1996;60:424-34
of transdermal nicotine. 1996;60:308-15 Yang CS (see Chen et al). 1996;60:651-60
van der Horst CM (see Knupp et al). 1996;60:535-42 Yau MK (see Anderson et al). 1996;60:145-56
van Griensven JMT, Huisman LGM, Stuurman T, Dooijewaard G, Yost RA (see Ameer et al). 1996;60:34-40
Kroon R, Schoemaker RC, Kluft K, Cohen AF. Effects of
increased liver blood flow on the kinetics and dynamics of recom- Z
binant tissue-type plasminogen activator. 1996;60:504-11 Zhou LX, Pihlstrom B, Hardwick JP, Park SS, Wrighton SA,
van Marle SP (see Weber et al). 1996;60:124-37 Holtzman JL. Metabolism of phenytoin by the gingiva of normal
Varhe A (see Neuvonen et al). 1996;60:326-31 humans: the possible role of reactive metabolites of phenytoin
Verotta D (see Gries et al). 1996;60:385-95 inthe initiation of gingival hyperplasia. 1996;60:191-8
Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Ziegler MG (see Mills et al). 1996;60:99-104
Cohen AF, Ferrari MD. Pharmacokinetic and pharmacodynamic
profiles of sumatriptan in migraine patients with headache recur-
rence or no response. 1996;60:452-60
Subject index
Relationship btween pharmacodynamic activity and cognitive effects of
eptastigmine in patients with Alzheimer’s disease (Canal et al).
Abafilcon A 1996;60:218-28
Abafilcon A (USAN List No. 387). 1996;60:484 American Society for Clinical Pharmacology and Therapeutics
Acetaminophen 1997 ASCPT Clinical Pharmacology Curriculum Review Course
The complex interaction between ethanol and acetaminophen (Slattery (Abernethy and Woosley). 1996;60:699
et al). 1996;60:241-6 (Commentary) Future meeting dates and sites. 1996;60:115, 236
Decrease of plasma and urinary oxidative metabolites of acetaminophen A message from the Education Committee chairman (Gray).
after consumption of watercress by human volunteers (Chen et al). 1996;60:236
1996;60:65 1-60 A message from the Ethics Committee chairman (Dunton).
Acetyltransferase 1996;60:360
N-Acetyltransferase 2 polymorphism in patients infected with human A message from the Finance Committee chairperson (Weinshilboum).
1996;60:480
immunodeficiency virus (Kaufmann et al). 1996;60:62-7
A message from the president—come to San Diego, California, March
Adefovir dipivoxil
5-8, 1997 (Atkinson). 1996;60:699
Adefovir dipivoxil (USAN List No. 385). 1996;60:237 A message from the Scientific Program Committee chairperson: 1997
Administration, cutaneous annual meeting—March 5-7 (ASCPT), March 8 (ASCPT/ASPET)
Exposure to high ambient temperature increases absorption and plasma (Schwartz). 1996;60:115
concentrations of transdermal nicotine (Vanakoski et al). Nominations for awards. 1996;60:358-9
1996;60:308-15 Amitriptyline
Administration, nasal Effects of divalproex sodium on amitriptyline and nortriptyline phar-
The absolute bioavailability and pharmacokinetics of butorphanol nasal macokinetics (Wong et al). 1996;60:48-53
spray in patients with hepatic impairment (Vachharajani et al). Amlodipine
1996;60:283-94 Valsartan, a new angiotensin II antagonist for the treatment of essential
Human pharmacokinetics of dihydroergotamine administered by nasal hypertension: a comparative study of the efficacy and safety against
spray (Humbert et al). 1996;60:265-75
amlodipine (Corea et al). 1996;60:341-6
Administration, oral Analgesics
Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron The hypoalgesic effect of tramadol in relation to CYP2D6 (Poulsen et
mesylate after oral or intravenous administration to anesthetized chil- al). 1996;60:636-44
dren (Lerman et al). 1996;60:485-92 Population pharmacodynamic model for ketorolac analgesia (Mandema
Administration, topical and Stanski). 1996;60:619-35
Safe and effective topical application dose of lidocaine for surgery with Angioneurotic edema
laryngomicroscopy (Kotaki et al). 1996;60:229-35 Black Americans have an increased rate of angiotensin converting
Adverse drug reactions enzyme inhibitor—associated angioedema (Brown et al). 1996;60:8-13
Adverse nondrug reactions: an update (Meyer et al). 1996;60:347-52 Angiotensin II
African-Americans Valsartan, a new angiotensin II antagonist for the treatment of essential
Black Americans have an increased rate of angiotensin converting hypertension: a comparative study of the efficacy and safety against
enzyme inhibitor—associated angioedema (Brown et al). 1996;60:8-13 amlodipine (Corea et al). 1996;60:341-6
Determination of CYP2C19 phenotype in black Americans with Angiotensin-converting enzyme inhibitors
omeprazole: correlation with genotype (Marinac et al). 1996;60:138- Black Americans have an increased rate of angiotensin converting
44 enzyme inhibitor—associated angioedema (Brown et al). 1996;60:8-13
Higher incidence of discontinuation of angiotensin converting enzyme Higher incidence of discontinuation of angiotensin converting enzyme
inhibitors due to cough in black subjects (Elliott). 1996;60:582-8 inhibitors due to cough in black subjects (Elliott). 1996;60:582-8
Aged Antibodies, heterophile
Cardiovascular adaptation to orthostatic stress during vasodilator ther- A new interference in some digoxin assays: anti-murine heterophilic
apy (Lipsitz et al). 1996;60:461-71 antibodies (Liendo et al). 1996;60:593-8
Albumin Antibodies, monoclonal
Effects of benazepril and nicardipine on microalbuminuria in nor- Recombinant protein and therapeutic monoclonal antibody drug devel-
motensive and hypertensive patients with diabetes (De Cesaris et al). opment in the United States from 1980 to 1994 (Gosse et al).
1996;60:472-8 1996;60:608-18 (Commentary)
Alcohol, ethyl Antihypertensive agents
The complex interaction between ethanol and acetaminophen (Slattery Reserpine: a tragic victim of myths, marketing, and fashionable pre-
et al). 1996;60:241-6 (Commentary) scribing (Fraser). 1996;60:368-73 (Commentary)
Alpha-adrenergic receptors; see Receptors, adrenergic, alpha Aptiganel hydrochloride
Alzheimer’s disease Aptiganel hydrochloride (USAN List No. 387). 1996;60:483
Clinical pharmacokinetics of arecoline in subjects with Alzheimer’s dis- Arcitumomab
ease (Asthana et al). 1996;60:276-82 Arcitumomab (USAN List No. 385). 1996;60:238
710 DECEMBER 1996 CLINICAL PHARMACOLOGY & THERAPEUTICS
CLINICAL PHARMACOLOGY & THERAPEUTICS Subject index 711
VOLUME 60, NUMBER 6
Arecoline Caffeine
Clinical pharmacokinetics of arecoline in subjects with Alzheimer’s dis- The effect of ephedrine plus caffeine on smoking cessation and postces-
ease (Asthana et al). 1996;60:276-82 sation weight gain (Ngrregaard et al). 1996;60:679-86
Atorvastatin Canada
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of Survey of clinical pharmacology training in the United States and
atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects Canada (Cantilena and Woosley). 1996;60:1-7
(Cilla et al). 1996;60:687-95
Cardiotoxicity; see Heart, toxicity
Azelaic acid
Cefpirome
Azelaic acid (USAN List No. 386). 1996;60:362 Multiple-dose pharmacokinetics of cefpirome in long-term hemodialy-
sis with high-flux membranes (Thalhammer et al). 1996;60:645-50
Cerivastatin sodium
Cerivastatin sodium (USAN List No. 385). 1996;60:237
Becaplermin Child; see also Infant
Becaplermin (USAN List No. 384). 1996;60:117 Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron
Benazepril mesylate after oral or intravenous administration to anesthetized chil-
Effects of benazepril and nicardipine on microalbuminuria in nor- dren (Lerman et al). 1996;60:485-92
motensive and hypertensive patients with diabetes (De Cesaris et al). Thiopurine methyltransferase activity in a Korean population sample of
1996;60:472-8 children (Park-Hah et al). 1996;60:68-74
Berger’s disease; see Glomerulonephritis, IgA China
Beta-adrenergic receptors; see Receptors, adrenergic, beta Differences between white subjects and Chinese subjects on the in vivo
inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole
Bioavailability
(Caraco et al). 1996;60:396-404
Interpatient variability in bioavailability is related to the extent of
Ethnic and genetic determinants of omeprazole disposition and effect
absorption: implications for bioavailability and bioequivalence stud-
(Caraco et al). 1996;60: 157-67
ies (Hellriegel et al). 1996;60:601-7 (Commentary)
Formation of morphine from codeine in Chinese subjects of different
Black Americans; see African-Americans CYP2D6 genotypes (Tseng et al). 1996;60:177-82
Books received Circadian rhythm
Books received. 1996;60:240 Chronopharmacokinetics of nicotine (Gries et al). 1996;60:385-95
Bosentan Clinical pharmacology
Pharmacokinetics and pharmacodynamics of the endothelin-receptor The challenge of in-hospital medication use: an opportunity for clinical
antagonist bosentan in healthy human subjects (Weber et al). pharmacology (Atkinson and Nordstrom). 1996;60:363-7
1996;60: 124-37 (Commentary)
Brain Survey of clinical pharmacology training in the United States and
Cerebral and ocular hemodynamic effects of sumatriptan in the nitro- Canada (Cantilena and Woosley). 1996;60: 1-7
glycerin headache model (Schmetterer et al). 1996;60:199-205 Clinical trials
Budesonide Adverse nondrug reactions: an update (Meyer et al). 1996;60:347-52
A comparison of nebulized budesonide with oral prednisolone in the Factors often not considered before a multicenter trial is started
treatment of exacerbations of obstructive pulmonary disease (Morice (Hardy). 1996;60:121-3 (Commentary)
et al). 1996;60:675-8 Medical histories may be unreliable in screening volunteers for clinical
trials (Apseloff et al). 1996;60:353-6
Bumetanide
Analysis of the variability in the pharmacokinetics and pharmacody- Codeine
namics of bumetanide in critically ill infants (Sullivan et al). Formation of morphine from codeine in Chinese subjects of different
1996;60:414-23 CYP2D6 genotypes (Tseng et al). 1996;60:177-82
Dose-ranging evaluation of bumetanide pharmacodynamics in critically Cognition
ill infants (Sullivan et al). 1996;60:424-34 Relationship btween pharmacodynamic activity and cognitive effects of
Pharmacokinetics of bumetanide in critically ill infants (Sullivan et al). eptastigmine in patients with Alzheimer’s disease (Canal et al).
1996;60:405-13 1996;60:2 18-28
Buprenorphine Commentaries
Buprenorphine and naloxone interactions in opiate-dependent vol- Commentaries. 1996;60:121-3, 241-54, 363-73
unteers (Mendelson et al). 1996;60: 105-14
Continuous ambulatory peritoneal dialysis; see Dialysis
Buspirone Correction
Efficacy of buspirone in smoking cessation: a placebo-controlled trial A case of bleeding requiring hospitalization that was likely caused by
(Schneider et al). 1996;60:568-75 an interaction between warfarin and levamisole (Wehbe and Warth)
Butorphanol (1996;59:360-2). 1996;60:137
The absolute bioavailability and pharmacokinetics of butorphanol nasal Correspondence; see Letters
spray in patients with hepatic impairment (Vachharajani et al).
1996;60:283-94 Costs and cost analysis
Cost-effectiveness analysis of serum vancomycin concentration moni-
toring in patients with hematologic malignancies (Fernandez de Gatta
€ et al). 1996;60:332-40
The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screen-
Cabergoline ing costs and influence on clinical outcomes in psychiatry (Chen et
Cabergoline (USAN List No. 386). 1996;60:361 al). 1996;60:522-34
CLINICAL PHARMACOLOGY & THERAPEUTICS
712 Subject index
DECEMBER 1996
Cough Dialysis
Higher incidence of discontinuation of angiotensin converting enzyme Disposition of didanosine in HIV-seropositive patients with normal
inhibitors due to cough in black subjects (Elliott). 1996;60:582-8 renal function or chronic renal failure: influence of hemodialysis and
continuous ambulatory peritoneal dialysis (Knupp et al).
Critical iliness
1996;60:535-42
Analysis of the variability in the pharmacokinetics and pharmacody-
namics of bumetanide in critically ill infants (Sullivan et al). Didanosine
1996;60:414-23 Disposition of didanosine in HIV-seropositive patients with normal
Dose-ranging evaluation of bumetanide pharmacodynamics in critically renal function or chronic renal failure: influence of hemodialysis and
ill infants (Sullivan et al). 1996;60:424-34 continuous ambulatory peritoneal dialysis (Knupp et al).
Pharmacokinetics of bumetanide in critically ill infants (Sullivan et al). 1996;60:535-42
1996;60:405-13 Diet
Cyclophosphamide Dietary salt restriction increases vascular insulin resistance (Feldman et
Regression of Henoch-Schénlein disease with intensive immunosup- al). 1996;60:444-51
pressive treatment (Faedda et al). 1996;60:576-81 Digoxin
Cytochrome P450 A new interference in some digoxin assays: anti-murine heterophilic
The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screen- antibodies (Liendo et al). 1996;60:593-8
ing costs and influence on clinical outcomes in psychiatry (Chen et A possible interaction of potential clinical interest between digoxin and
al). 1996;60:522-34 acarbose (Serrano et al). 1996;60:589-92
Determination of CYP2C19 phenotype in black Americans with Dihydroergotamine
omeprazole: correlation with genotype (Marinac et al). 1996;60:138- Human pharmacokinetics of dihydroergotamine administered by nasal
44 spray (Humbert et al). 1996;60:265-75
Determination of cytochrome P450 3A4/S5 activity in vivo with dex-
Diltiazem
tromethorphan N-demethylation (Jones et al). 1996;60:374-84
Pharmacokinetic and pharmacodynamic interactions between diltiazem
Differences between white subjects and Chinese subjects on the in vivo
and quinidine (Laganiére et al). 1996;60:255-64
inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole
(Caraco et al). 1996;60:396-404 Divalproex sodium
Dispositon of fluvoxamine in humans is determined by the polymorphic Divalproex sodium (USAN List No. 386). 1996;60:362
CYP2D6 and also by the CYPIA2 activity (Carrillo et al). Effects of divalproex sodium on amitriptyline and nortriptyline phar-
1996;60: 183-90 macokinetics (Wong et al). 1996;60:48-53
The hypoalgesic effect of tramadol in relation to CYP2D6 (Poulsen et Dolasetron
al). 1996;60:636-44 Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron
The influence of CYP2D6 polymorphism and quinidine on the disposi- mesylate after oral or intravenous administration to anesthetized chil-
tion and antitussive effect of dextromethorphan in humans (Capon et dren (Lerman et al). 1996;60:485-92
al). 1996;60:295-307 Drug absorption
Steady-state serum concentrations of the neuroleptic perphenazine in Exposure to high ambient temperature increases absorption and plasma
relation to CYP2D6 genetic polymorphism (Linnet and Wiborg). concentrations of transdermal nicotine (Vanakoski et al).
1996;60:41-7 1996;60:308-15
Flavanone absorption after naringin, hesperidin, and citrus administra-
D tion (Ameer et al). 1996;60:34-40
Interpatient variability in bioavailability is related to the extent of
Danaparoid sodium absorption: implications for bioavailability and bioequivalence stud-
Danaparoid sodium (USAN List No. 387). 1996;60:484 ies (Hellriegel et al). 1996;60:601-7 (Commentary)
Debrisoquin Drug clearance
The disposition of fluoxetine but not sertraline is altered in poor metab- Chronopharmacokinetics of nicotine (Gries et al). 1996;60:385-95
olizers of debrisoquin (Hamelin et al). 1996;60:512-21 Drug development
Desmopressin Recombinant protein and therapeutic monoclonal antibody drug devel-
Abnormal desmopressin-induced forearm vasodilatation in patients opment in the United States from 1980 to 1994 (Gosse et al).
with heart failure: dependence on nitric oxide synthase activity 1996;60:608-18 (Commentary)
(Rector et al). 1996;60:667-74
Drug interactions
Dexsotalol hydrochloride Bidirectional interaction of valproate and lamotrigine in healthy sub-
Dexsotalol hydrochloride (USAN List No. 384). 1996;60:120 jects (Anderson et al). 1996;60:145-56
Dextromethorphan Buprenorphine and naloxone interactions in opiate-dependent volun-
Determination of cytochrome P450 3A4/5 activity in vivo with dex- teers (Mendelson et al). 1996;60:105-14
tromethorphan N-demethylation (Jones et al). 1996;60:374-84 The complex interaction between ethanol and acetaminophen (Slattery
The influence of CYP2D6 polymorphism and quinidine on the disposi- et al). 1996;60:241-6 (Commentary)
tion and antitussive effect of dextromethorphan in humans (Capon et The effect of ingestion time interval on the interaction between itra-
al). 1996;60:295-307 conazole and triazolam (Neuvonen et al). 1996;60:326-31
Effects of divalproex sodium on amitriptyline and nortriptyline phar-
Dezocine
macokinetics (Wong et al). 1996;60:48-53
Opioid antagonist effects of dezocine in opioid-dependent humans
Erythromycin-felodipine interaction: magnitude, mechanism, and com-
(Strain et al). 1996;60:206-17
parison with grapefruit juice (Bailey et al). 1996;60:25-33
Diabetes Flavanone absorption after naringin, hesperidin, and citrus administra-
Effects of benazepril and nicardipine on microalbuminuria in nor- tion (Ameer et al). 1996;60:34-40
motensive and hypertensive patients with diabetes (De Cesaris et al). Itraconazole drastically increases plasma concentrations of lovastatin
1996;60:472-8 and lovastatin acid (Neuvonen and Jalava). 1996;60:54-61
CLINICAL PHARMACOLOGY & THERAPEUTICS Subject index. 713
VOLUME 60, NUMBER 6
Pharmacokinetic and pharmacodynamic interactions between diltiazem Eye
and quinidine (Laganiére et al). 1996;60:255-64 Cerebral and ocular hemodynamic effects of sumatriptan in the nitro-
A possible interaction of potential clinical interest between digoxin and glycerin headache model (Schmetterer et al). 1996;60:199-205
acarbose (Serrano et al). 1996;60:589-92
Drug therapy F
The challenge of in-hospital medication use: an opportunity for clinical
Felodipine
pharmacology (Atkinson and Nordstrom). 1996;60:363-7
Erythromycin-felodipine interaction: magnitude, mechanism, and com-
(Commentary) parison with grapefruit juice (Bailey et al). 1996;60:25-33
Drug tolerance Flavanone
Pharmacodynamic modeling of furosemide tolerance after multiple Flavanone absorption after naringin, hesperidin, and citrus administra-
intravenous administration (Wakelkamp et al). 1996;60:75-88 tion (Ameer et al). 1996;60:34-40
Fluoxetine
E The disposition of fluoxetine but not sertraline is altered in poor metab-
olizers of debrisoquin (Hamelin et al). 1996;60:512-21
Edrecolomab
Edrecolomab (USAN List No. 387). 1996;60:481 Fluvastatin
Jejunal permeability and hepatic extraction of fluvastatin in humans
Education (Lindahl et al). 1996;60:493-503
Survey of clinical pharmacology training in the United States and
Fluvoxamine
Canada (Cantilena and Woosley). 1996;60: 1-7
Dispositon of fluvoxamine in humans is determined by the polymorphic
Eldacimibe CYP2D6 and also by the CYPIA2 activity (Carrillo et al).
Eldacimibe (USAN List No. 386). 1996;60:362 1996;60: 183-90
Electrocardiography Food-drug interactions
Stereoselective cardiotoxic effects of terodiline (Hartigan-Go et al). Decrease of plasma and urinary oxidative metabolites of acetaminophen
1996;60:89-98 after consumption of watercress by human volunteers (Chen et al).
Endothelins 1996;60:65 1-60
Erythromycin-felodipine interaction: magnitude, mechanism, and com-
Pharmacokinetics and pharmacodynamics of the endothelin-receptor
parison with grapefruit juice (Bailey et al). 1996;60:25-33
antagonist bosentan in healthy human subjects (Weber et al).
Flavanone absorption after naringin, hesperidin, and citrus administra-
1996;60: 124-37
tion (Ameer et al). 1996;60:34-40
Enzymes
Furosemide
The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screen-
Pharmacodynamic modeling of furosemide tolerance after multiple
ing costs and influence on clinical outcomes in psychiatry (Chen et intravenous administration (Wakelkamp et al). 1996;60:75-88
al). 1996;60:522-34
Ephedrine G
The effect of ephedrine plus caffeine on smoking cessation and postces-
sation weight gain (Ngrregaard et al). 1996;60:679-86 Gender factors
The effects of the menstrual cycle, race, and gender on adrenergic
Eptastigmine
receptors and agonists (Mills et al). 1996;60:99-104
Relationship btween pharmacodynamic activity and cognitive effects of
eptastigmine in patients with Alzheimer’s disease (Canal et al). Genotype
1996;60:218-28 Determination of CYP2C19 phenotype in black Americans with
omeprazole: correlation with genotype (Marinac et al). 1996;60:138-
Erythromycin a4
Erythromycin-felodipine interaction: magnitude, mechanism, and com- Formation of morphine from codeine in Chinese subjects of different
parison with grapefruit juice (Bailey et al). 1996;60:25-33 CYP2D6 genotypes (Tseng et al). 1996;60:177-82
Essential hypertension; see Hypertension Genotyping of S-mephenytoin 4°’-hydroxylation in an extended
Japanese population (Kubota et al). 1996;60:661-6
Ethanol; see Alcohol, ethyl
Gingiva
Ethnic factors
Metabolism of phenytoin by the gingiva of normal humans: the possi-
Black Americans have an increased rate of angiotensin converting ble role of reactive metabolites of phenytoin in the initiation of gingi-
enzyme inhibitor—associated angioedema (Brown et al). 1996;60:8-13 val hyperplasia (Zhou et al). 1996;60:191-8
Differences between white subjects and Chinese subjects on the in vivo
Glomerulonephritis, IgA
inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole
Immunosuppressive treatment of Berger’s disease (Faedda et al).
(Caraco et al). 1996;60:396-404
1996;60:561-7
The effects of the menstrual cycle, race, and gender on adrenergic
Glucuronidation
receptors and agonists (Mills et al). 1996;60:99-104
Ethnic and genetic determinants of omeprazole disposition and effect Pharmacokinetics of morphine and its glucuronides after intravenous
infusion of morphine and morphine-6-glucuronide in healthy volun-
(Caraco et al). 1996;60: 157-67
Formation of morphine from codeine in Chinese subjects of different teers (Létsch et al). 1996;60:316-25
CYP2D6 genotypes (Tseng et al). 1996;60:177-82 Grapefruit juice
Genotyping of S-mephenytoin 4°-hydroxylation in an extended Erythromycin-felodipine interaction: magnitude, mechanism, and com-
Japanese population (Kubota et al). 1996;60:661-6 parison with grapefruit juice (Bailey et al). 1996;60:25-33
Higher incidence of discontinuation of angiotensin converting enzyme Flavanone absorption after naringin, hesperidin, and citrus administra-
inhibitors due to cough in black subjects (Elliott). 1996;60:582-8 tion (Ameer et al). 1996;60:34-40
Thiopurine methyltransferase activity in a Korean population sample of Guest reviewers
children (Park-Hah et al). 1996;60:68-74 Guest reviewers. 1996;60:479
CLINICAL PHARMACOLOGY & THERAPEUTICS
714 Subject index
DECEMBER 1996
H Hypertension
Cardiovascular adaptation to orthostatic stress during vasodilator ther-
Hand apy (Lipsitz et al). 1996;60:461-71
Substance P in human hand veins in vivo: tolerance, efficacy, potency, Effects of benazepril and nicardipine on microalbuminuria in nor-
and mechanism of venodilator action (Strobel et al). 1996;60:435-43 motensive and hypertensive patients with diabetes (De Cesaris et al).
Headache 1996;60:472-8
Cerebral and ocular hemodynamic effects of sumatriptan in the nitro- Valsartan, a new angiotensin II antagonist for the treatment of essential
glycerin headache model (Schmetterer et al). 1996;60: 199-205 hypertension: a comparative study of the efficacy and safety against
Pharmacokinetic and pharmacodynamic profiles of sumatriptan in amlodipine (Corea et al). 1996;60:341-6
migraine patients with headache recurrence or no response (Visser et
al). 1996;60:452-60
Heart, toxicity
Stereoselective cardiotoxic effects of terodiline (Hartigan-Go et al). Idoxifene
1996;60:89-98 Idoxifene (USAN List No. 389). 1996;60:700
Heart failure, congestive Immune globulin intravenous pentetate
Abnormal desmopressin-induced forearm vasodilatation in patients Immune globulin intravenous pentetate (USAN List No. 387).
with heart failure: dependence on nitric oxide synthase activity 1996;60:484
(Rector et al). 1996;60:667-74 Immunosuppressive agents
Hematologic diseases Immunosuppressive treatment of Berger’s disease (Faedda et al).
Cost-effectiveness analysis of serum vancomycin concentration moni- 1996;60:561-7
toring in patients with hematologic malignancies (Fernandez de Gatta Regression of Henoch-Schénlein disease with intensive immunosup-
et al). 1996;60:332-40 pressive treatment (Faedda et al). 1996;60:576-81
Hemodialysis Infant
Disposition of didanosine in HIV-seropositive patients with normal Analysis of the variability in the pharmacokinetics and pharmacody-
renal function or chronic renal failure: influence of hemodialysis and namics of bumetanide in critically ill infants (Sullivan et al).
continuous ambulatory peritoneal dialysis (Knupp et al). 1996;60:414-23
1996;60:535-42 Dose-ranging evaluation of bumetanide pharmacodynamics in critically
Multiple-dose pharmacokinetics of cefpirome in long-term hemodialy- ill infants (Sullivan et al). 1996;60:424-34
sis with high-flux membranes (Thalhammer et al). 1996;60:645-50 Pharmacokinetics of bumetanide in critically ill infants (Sullivan et al).
Hemodynamics 1996;60:405-13
Cerebral and ocular hemodynamic effects of sumatriptan in the nitro- Infusions, intravenous
glycerin headache model (Schmetterer et al). 1996;60:199-205 Pharmacokinetics of morphine and its glucuronides after intravenous
Henoch-Schonlein disease; see Purpura, Schénlein-Henoch infusion of morphine and morphine-6-glucuronide in healthy volun-
teers (Létsch et al). 1996;60:316-25
Hepatic diseases; see Liver diseases
Injections, intravenous
Hesperidin
Pharmacodynamic modeling of furosemide tolerance after multiple
Flavanone absorption after naringin, hesperidin, and citrus administra-
intravenous administration (Wakelkamp et al). 1996;60:75-88
tion (Ameer et al). 1996;60:34-40
Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron
Heterophilic antibodies; see Antibodies, heterophile mesylate after oral or intravenous administration to anesthetized chil-
Hioxifilcon A dren (Lerman et al). 1996;60:485-92
Hioxifilcon A (USAN List No. 384). 1996;60:117 Insulin
HIV Dietary salt restriction increases vascular insulin resistance (Feldman et
N-Acetyltransferase 2 polymorphism in patients infected with human al). 1996;60:444-51
immunodeficiency virus (Kaufmann et al). 1996;60:62-7 Intestines
Disposition of didanosine in HIV-seropositive patients with normal First-pass metabolism of midazolam by the human intestine (Paine et
renal function or chronic renal failure: influence of hemodialysis and al). 1996;60:14-24
continuous ambulatory peritoneal dialysis (Knupp et al).
1996;60:535-42 Intravenous infusions; see Infusions, intravenous
Zidovudine phosphorylation after short-term and long-term therapy Intravenous injections; see Injections, intravenous
with zidovudine in patients infected with the human immunodefi-
Irbesartan
ciency virus (Peter and Gambertoglio). 1996;60: 168-76
Irbesartan (USAN List No. 389). 1996;60:701
Hospitals
Itasetron
The challenge of in-hospital medication use: an opportunity for clinical
Itasetron (USAN List No. 387). 1996;60:483
pharmacology (Atkinson and Nordstrom). 1996;60:363-7
(Commentary) Itraconazole
The effect of ingestion time interval on the interaction between itra-
Human immunodeficiency virus; see HIV
conazole and triazolam (Neuvonen et al). 1996;60:326-31
Hydroxy-methylglutaryl coenzyme A Itraconazole drastically increases plasma concentrations of lovastatin
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of and lovastatin acid (Neuvonen and Jalava). 1996;60:54-61
atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects
(Cilla et al). 1996;60:687-95
Hyperplasia
Metabolism of phenytoin by the gingiva of normal humans: the possi- Japan
ble role of reactive metabolites of phenytoin in the initiation of gingi- Genotyping of S-mephenytoin 4’-hydroxylation in an extended
val hyperplasia (Zhou et al). 1996;60:191-8 Japanese population (Kubota et al). 1996;60:661-6